Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares Repurchased
Ratios

Core Laboratories (CLB) Long-Term Debt Repayments (2022 - 2026)

Core Laboratories filings provide 5 years of Long-Term Debt Repayments readings, the most recent being $62.0 million for Q1 2026.

  • On a quarterly basis, Long-Term Debt Repayments rose 313.33% to $62.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $110.0 million, a 37.5% increase, with the full-year FY2025 number at $63.0 million, down 23.17% from a year prior.
  • Long-Term Debt Repayments hit $62.0 million in Q1 2026 for Core Laboratories, up from $16.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $85.0 million in Q2 2023 to a low of $12.0 million in Q2 2025.
  • Median Long-Term Debt Repayments over the past 5 years was $20.0 million (2024), compared with a mean of $34.5 million.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 361.11% in 2023 and later plummeted 75.29% in 2024.
  • Core Laboratories' Long-Term Debt Repayments stood at $82.0 million in 2022, then tumbled by 67.07% to $27.0 million in 2023, then dropped by 25.93% to $20.0 million in 2024, then decreased by 20.0% to $16.0 million in 2025, then surged by 287.5% to $62.0 million in 2026.
  • The last three reported values for Long-Term Debt Repayments were $62.0 million (Q1 2026), $16.0 million (Q4 2025), and $20.0 million (Q3 2025) per Business Quant data.